We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Inflammation or ulceration of the mucous membrane of the upper respiratory passages or mouth by dust, liquid, or vapour: IIAC report.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
We want to remind healthcare professionals that use of systemic (oral and injectable) NSAIDs such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy).
Paper prepared by the Royal Society for the Scientific Advisory Group for Emergencies (SAGE).
Guidance on the cardiovascular safety of Cox-2 inhibitors and NSAIDs and further reading.
Zinc is a negative acute-phase reactant, so its concentration decreases in the presence of inflammation
This document contains a synopsis of causation occurring in Inflammatory Bowel Disease.
This review describes the antagonistic interaction between the Acute Phase Response and nutritional status
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
Projects granted during 2015 that have a primary purpose of basic research: immune system.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Find out what unacceptable or unreasonable actions are and how we approach them.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).